GLP1R and type 2 diabetes mellitus: Clinical anecdotes that patients treated with semaglutide, a glucagon-like peptide-1 receptor (GLP1R) agonist approved for treating type 2 diabetes (T2D) in 2017 and for weight management in 2021 reported reduced desire to drink and smoke have attracted attention regarding its potential to treat addiction [12].